Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane

Annelieke E. C. A. B. Willemsen, Jolien Tol, Nielka P. van Erp, Marianne A. Jonker, Maaike de Boer, Bob Meek, Paul C. de Jong, Coline van Moorsel, Winald R. Gerritsen, Jan C. Grutters, Carla M. L. van Herpen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)441-451
Number of pages11
JournalTargeted Oncology
Volume14
Issue number4
DOIs
Publication statusPublished - Aug 2019

Keywords

  • POSITRON-EMISSION-TOMOGRAPHY
  • INDUCED PNEUMONITIS
  • PULMONARY TOXICITY
  • MANAGEMENT
  • INHIBITOR
  • BIOMARKERS

Cite this

Willemsen, A. E. C. A. B., Tol, J., van Erp, N. P., Jonker, M. A., de Boer, M., Meek, B., de Jong, P. C., van Moorsel, C., Gerritsen, W. R., Grutters, J. C., & van Herpen, C. M. L. (2019). Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. Targeted Oncology, 14(4), 441-451. https://doi.org/10.1007/s11523-019-00656-2